Early CPAP in COVID-19 Patients With Respiratory Failure. (EC-COVID-RCT)
Primary Purpose
CPAP Ventilation, COVID-19, Emergency Departments
Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
CPAP treatment
Sponsored by
About this trial
This is an interventional treatment trial for CPAP Ventilation
Eligibility Criteria
Inclusion Criteria:
ED patients positive to or suspected of COVID-19 infection with at least one of the following symptoms:
- fever
- cough/dyspnea
- respiratory symptoms or ED arrival for respiratory reason and for whom there are the following conditions:
- SpO2 < 95% in ambient air or positive Quick Walk Test
- PaO2/FiO2 > 200 in ambient air or with Venturi mask, evaluated in 1 hour from ED arrival.
Exclusion Criteria:
- BPCO patients
- Age > 70 years
- Pregnant status
- Contraindications for CPAP
Sites / Locations
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Early CPAP treatment
Control
Arm Description
Early treatment with CPAP in addition to current clinical practice
Current clinical practice, which currently does not involve the use of CPAP.
Outcomes
Primary Outcome Measures
Death or need of intubation
The study outcomes will be death or need of intubation within 7 days since ED arrival.
Secondary Outcome Measures
30-day mortality
30-day mortality
Full Information
NCT ID
NCT04326075
First Posted
March 26, 2020
Last Updated
December 16, 2022
Sponsor
Mario Negri Institute for Pharmacological Research
1. Study Identification
Unique Protocol Identification Number
NCT04326075
Brief Title
Early CPAP in COVID-19 Patients With Respiratory Failure.
Acronym
EC-COVID-RCT
Official Title
EC-COVID-RCT. Early CPAP in COVID Patients With Respiratory Failure. A Randomized Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
December 2021
Overall Recruitment Status
Completed
Study Start Date
December 1, 2020 (Actual)
Primary Completion Date
June 30, 2021 (Actual)
Study Completion Date
December 15, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mario Negri Institute for Pharmacological Research
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The study aims at clarifying whether early treatment with continuous positive airway pressure (CPAP) ventilation is able to reduce the need for intubation or death in patients visiting an emergency department (ED) with known or suspected COVID-19 infection and insufficiency respiratory.
Detailed Description
Eligible patients will be randomized to two treatment arms: current clinical practice (control arm) and early treatment with CPAP in addition to current clinical practice (experimental arm). To deal with the current emergency situation, the study will adopt an adaptive design with a Bayesian continuous monitoring. Such design allows to stop the study as soon as the data provide sufficient evidence of efficacy or ineffectiveness of the studied treatment.
The primary endpoint of the study is the combination of intubation or death within 7 days of randomization. The secondary endpoint is 30-day mortality.
All patients arriving at the ED will be evaluated to verify the presence of inclusion and exclusion criteria. Randomization will be performed through an ad-hoc electronic case report form (eCRF). Eligible patients should be randomized as soon as possible, possibly immediately after the ED triage.
Patients randomized to the control arm will be treated according to current clinical practice, which currently does not involve the use of CPAP. Therefore, these patients should not start treatment with CPAP immediately after randomization. CPAP treatment, however, is allowed at a later stage, if deemed appropriate according to clinical judgment.
Patients randomized to the experimental arm should begin treatment with CPAP as soon as possible. CPAP should only be performed with a helmet, using a positive end-expiratory pressure (PEEP) between 8 and 14 cmH2O and an inspired oxygen fraction (FiO2) between 40 and 60%. FiO2 and PEEP must be modulated, within the limits indicated above, so as to obtain a saturation > 94%. Whenever this goal cannot be achieved, the patient should be referred to the intensivist.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
CPAP Ventilation, COVID-19, Emergency Departments
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
68 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Early CPAP treatment
Arm Type
Experimental
Arm Description
Early treatment with CPAP in addition to current clinical practice
Arm Title
Control
Arm Type
No Intervention
Arm Description
Current clinical practice, which currently does not involve the use of CPAP.
Intervention Type
Device
Intervention Name(s)
CPAP treatment
Intervention Description
CPAP should be performed as soon as possible and only with a helmet, using a positive end-expiratory pressure (PEEP) between 8 and 14 cmH2O and an inspired oxygen fraction (FiO2) between 40 and 60%.
Primary Outcome Measure Information:
Title
Death or need of intubation
Description
The study outcomes will be death or need of intubation within 7 days since ED arrival.
Time Frame
7 days since ED arrival
Secondary Outcome Measure Information:
Title
30-day mortality
Description
30-day mortality
Time Frame
30 days since ED arrival
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
ED patients positive to or suspected of COVID-19 infection with at least one of the following symptoms:
fever
cough/dyspnea
respiratory symptoms or ED arrival for respiratory reason and for whom there are the following conditions:
SpO2 < 95% in ambient air or positive Quick Walk Test
PaO2/FiO2 > 200 in ambient air or with Venturi mask, evaluated in 1 hour from ED arrival.
Exclusion Criteria:
BPCO patients
Age > 70 years
Pregnant status
Contraindications for CPAP
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guido Bertolini, MD
Organizational Affiliation
Istituto di Ricerche Farmacologiche Mario Negri IRCCS
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
City
Milan
ZIP/Postal Code
20122
Country
Italy
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Early CPAP in COVID-19 Patients With Respiratory Failure.
We'll reach out to this number within 24 hrs